

## SECTION 708A NOTICE

---

This notice is given by Aroa Biosurgery Limited (**Company**) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

- (a) it has today issued:
  - a. 102,400 fully paid ordinary shares at a A\$0.75 issue price per share as the result of the exercise of unlisted options held by a director of the Company; and
  - b. 3,525,000 Unlisted Options exercisable at A\$1.165, expiring 8 August 2026 to employees of the Company under its Employee Share Option Plans.
- (b) the shares referred to in paragraph (a) above were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) Section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Appendix 2A and Appendix 3G documents relating to the above issues will follow shortly.

< ENDS >

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

**About Aroa Biosurgery:**

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody', its products are developed from the Company's proprietary Aroa ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Aroa's products have been used in more than four million procedures to date, with distribution into its key market of the United States by its direct sales force and its partner TELA Bio, Inc. Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). [www.aroabio.com/](http://www.aroabio.com/)

ASX ANNOUNCEMENT/MEDIA RELEASE  
19 AUGUST 2021



**Contacts**

*Investor*

Simon Hinsley

Investor Relations

[shinsley@aroabio.com](mailto:shinsley@aroabio.com)

+ 61 401 809 653

*Media*

Australia

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

+61 451 896 420

New Zealand

Piet De Jong

[piet.dejong@baldwinboyle.com](mailto:piet.dejong@baldwinboyle.com)

+64 21 812 766